Evaluating botulinum toxin products for clinical use requires accurate, complete, and unbiased data

Andy PickettToxin Science Limited, Wrexham, UK; Botulinum Research Center, UMASS Dartmouth, MA, USACorrespondence[email protected]

Pages 1287-1290 | Published online: 09 Sep 2011

Cite this article

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

PickettACairdDComparison of type a botulinum toxin products in clinical useJ Clin Pharm Ther200833332732818452421
PubMed Web of Science ®Google Scholar
PickettADoddSRzanyBConfusion about diffusion and the art of misinterpreting data when comparing different botulinum toxins used in aesthetic applicationsJ Cosmet Laser Ther200810318118318608706
PubMed Web of Science ®Google Scholar
PickettADysport®: Pharmacological properties and factors that influence toxin actionToxicon200954568368919332087
PubMed Web of Science ®Google Scholar
ParkJLeeMSHarrisonARProfile of Xeomin® (incobotulinumtoxinA) for the treatment of blepharospasmClin Ophthalmol2011572573221691580
PubMedGoogle Scholar
PickettAPerrowKFormulation composition of botulinum toxins in clinical useJ Drugs Dermatol2010991085109120865839
PubMed Web of Science ®Google Scholar
EiseleK-HFinkKVeyMTaylorHVStudies on the dissociation of botulinum neurotoxin type A complexesToxicon201157455556521195107
PubMed Web of Science ®Google Scholar
FangP-KRaphaelBMaslankaSCaiSSinghBAnalysis of genomic differences among Clostridium botulinum type A1 strainsBMC Genomics201011172521182778
PubMed Web of Science ®Google Scholar
PickettAConsistent Biochemical data are essential for comparability of botulinum toxin type A productsDrugs R D2011111979821410299
PubMedGoogle Scholar
DresslerDRoutine use of Xeomin® in patients previously treated with Botox: long term resultsEur J Neurol200916Suppl 22520002739
PubMed Web of Science ®Google Scholar
FrevertJXeomin® is free from complexing proteinsToxicon200954569770119292989
PubMed Web of Science ®Google Scholar
LeeJCYokotaKArimitsuHProduction of anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin-haemagglutininMicrobiology2005151Pt 113739374716272395
PubMed Web of Science ®Google Scholar
AtassiMZOn the enhancement of anti-neurotoxin antibody production by subcomponents HA1 and HA3b of Clostridium botulinum type B 16S toxin-haemagglutininMicrobiology2006152Pt 71891189516804163
PubMed Web of Science ®Google Scholar
Xeomin^® prescribing information http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125360lbl.pdfAccessed July 19, 2011
Google Scholar
GreenePFahnSDiamondBDevelopment of resistance to botulinum toxin type A in patients with torticollisMov Disord1994922132178196686
PubMed Web of Science ®Google Scholar
BorodicGJohnsonEGoodnoughMSchantzEBotulinum toxin therapy, immunologic resistance, and problems with available materialsNeurology199646126298559392
PubMed Web of Science ®Google Scholar
BentivoglioARFasanoAIalongoTSoletiFLoFSAlbaneseAFifteen- year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugsNeurotox Res200915322423119384595
PubMed Web of Science ®Google Scholar
BlumelJFrevertJSchwaierAComparative antigenicity of three preparations of botulinum neurotoxin type A in the rabbitPaper presented at: 5th Triennial International Conference on Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins (Toxins 2005)2005Denver, Colorado, USA
Google Scholar
PanjwaniNO’KeeffeRPickettAMBiochemical, functional and potency characteristics of type A botulinum toxin in clinical useThe Botulinum Journal200811153166
Google Scholar
FrevertJContent of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®Drugs R D2010102677320698714
PubMedGoogle Scholar
FrevertJAuthor’s ReplyDrugs R D20111119899
Google Scholar
WabbelsBReichelGFulford-SmithAWrightNRoggenkamperPDouble-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasmJ Neural Transm2011118223323921161715
PubMed Web of Science ®Google Scholar
HappakWLiuJBurggasserGFlowersAGruberHFreilingerGHuman facial muscles: dimensions, motor endplate distribution, and presence of muscle fibers with multiple motor endplatesAnat Rec199724922762849335474
PubMedGoogle Scholar
RoggenkamperPJostWHBihariKComesGGrafeSEfficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasmJ Neural Transm2006113330331215959841
PubMed Web of Science ®Google Scholar
JankovicJComellaCHanschmannAGrafeSEfficacy and safety of NT 201 (botulinum neurotoxin free from complexing proteins) in blepharospasmPaper presented at: American Academy of Neurology 61st Annual Meeting2009Seattle, WA
Google Scholar
JankovicJComellaCHanschmannAGrafeSEfficacy and safety of incobotulinumtoxinA (NT 201, Xeomin®) in the treatment of blepharospasm – a randomized trialMov Disord20112681521152821520284
PubMed Web of Science ®Google Scholar
JankovicJKenneyCGrafeSGoertelmeyerRComesGRelationship between various clinical outcome assessments in patients with blepharospasmMov Disord200924340741319053054
PubMed Web of Science ®Google Scholar
JankovicJClinical efficacy and tolerability of Xeomin® in the treatment of blepharospasmEur J Neurol200916141820002742
PubMed Web of Science ®Google Scholar

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Evaluating botulinum toxin products for clinical use requires accurate, complete, and unbiased data

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Evaluating botulinum toxin products for clinical use requires accurate, complete, and unbiased data

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date